Relief Cardiovascular Secures $12M for Innovative Heart Failure Treatment
Relief Cardiovascular, a pioneering medical device company focused on innovative solutions for heart failure management, has successfully closed a $12 million Series A financing round. This significant funding milestone was co-led by Broadview Ventures and Advent Life Sciences, with additional participation from Pacific Health Investment, Heartwork Capital, and an undisclosed multinational strategic investor.
The funds secured through this financing round will be utilized to further develop Relief Cardiovascular’s flagship technology, the Relief System, and to initiate the company’s first-in-human feasibility study. The Relief System is a transcatheter smart implant designed to monitor and modulate renal vein pressures, offering a novel approach to fluid management in heart failure. This innovative technology addresses a critical gap in patient care by providing a tailored therapeutic device-driven intervention for optimizing fluid management.
As part of the financing agreement, Shahzad Malik, General Partner at Advent Life Sciences, and Maria Berkman, Head of Medtech at Broadview Ventures, will join Relief Cardiovascular’s Board of Directors. Their expertise and experience in the medical technology sector will be invaluable in guiding the company as it advances the Relief System into human clinical studies.
Heart failure continues to impose a significant burden on patients and healthcare systems worldwide. The Relief System’s ability to dynamically modulate renal vein pressures offers the potential to redefine treatment and improve outcomes for patients facing limited options, particularly those with diuretic-resistant heart failure.
The Relief System employs an innovative “puller” mechanism paired with integrated sensors that autonomously capture renal vein pressures and multiparametric data. This data-driven approach empowers physicians to make more personalized and effective care decisions for patients, particularly those with diuretic resistance.
Industry experts and clinicians have expressed their support for the Relief System. William T. Abraham, Professor of Medicine at The Ohio State University Wexner Medical Center, noted that the Relief System’s ability to integrate monitoring and therapeutic modulation of renal pressures represents a promising advance in volume management in heart failure. Alex Rothman, Professor of Cardiology at the University of Sheffield, emphasized that the Relief System enables data-driven adjustments, empowering more personalized and effective care for patients.
Alex Cooper, CEO of Relief Cardiovascular, highlighted the significance of this financing round, stating that it marks a pivotal milestone for the company as it advances the Relief System into human clinical studies. The support of world-class investors and clinicians, along with industry veterans like Michael Minogue, positions Relief Cardiovascular to transform the management and treatment of heart failure.
Relief Cardiovascular is a privately held medical device company committed to improving outcomes for patients with heart failure. The company was founded and incubated within inQB8 Medical Technologies, LLC, a medical device incubator specializing in developing cutting-edge interventional solutions for major cardiovascular diseases.
Broadview Ventures and Advent Life Sciences, the co-leaders of the financing round, are mission-driven investment organizations focused on accelerating the development of innovative therapeutics, devices, and diagnostics for cardiovascular disease and stroke. Their participation in this funding round underscores their commitment to supporting innovative solutions that address unmet medical needs.
With this significant funding, Relief Cardiovascular is poised to make a significant impact in the management and treatment of heart failure, offering hope to patients and healthcare systems worldwide.
See more funded startups in USA.